Risk of Injury According to Attention Deficit Hyperactivity Disorder, Comorbid Mental Illness, and Medication Therapy

Abstract

Introduction: We identify the risk of selected types of injuries among patients with ADHD or ADHD and comorbid mental illness. We also assess whether selected medications used by patients with ADHD increase the risk of comorbid mental illness or influence the association between ADHD and injury.

Methods: A retrospective cohort study design was conducted using medical claims data from the Deseret Mutual Benefit Administrators (DMBA). ADHD diagnosis, injury, medication, and demographic data were extracted from claims files during 2001–2013. Rate ratios were adjusted for age, sex, and calendar year.

Results: Patients with ADHD were 7.9 (95% CI 7.6–8.2) times more likely to have psychosis, 5.5 (3.9–7.8) times more likely to have alcohol- or drug-induced psychosis, and 6.0 (5.9–6.2) times more likely to have neurotic or personality disorder. Therapy with amphetamine was positively associated with neurotic or personality disorder (rate ratio=1.08, 1.02–1.15); methylphenidate was negatively associated with neurotic or personality disorder (0.90, 0.84–0.97); and atomoxetine was positively associated with psychosis (1.33, 1.21–1.46), alcohol- or drug-induced psychosis (2.38, 1.04–5.43), and neurotic or personality disorder (2.38, 1.04–5.43). ADHD was associated with an increased risk of injury, with ADHD and comorbid mental illness having a stronger increased risk of injury. Psychostimulants ameliorated the increased risk of injury for patients with ADHD.

Conclusion: Patients with ADHD have an increased risk of injury, significantly more so for those with ADHD and comorbid mental illness. Psychostimulants can lower the risk of injury among patients with ADHD.

Key words

ADHD - claims data - incidence - injury - retrospective cohort - risk

• References

• 1 Biederman J, Faraone SV. Attention-deficit hyper-activity disorder. Lancet 2006; 367: 210
• 2 Pearl PL, Weiss RE, Stein MA. Medical mimics: medical and neurological conditions simulating ADHD. Ann N Y Acad Sci 2001; 931: 97-112
• 3 Farmer JE, Peterson L. Injury risk factors in children with attention deficit hyperactivity disorder. Health Psychol 1995; 14: 325-332
• 4 Kessler RC, Lane M, Stang PE et al. The prevalence and workplace costs of adult attention deficit hyperactivity disorder in a large manufacturing firm. Psychol Med 2009; 39: 137-147
• 5 Leibson CL, Katusic SK, Barbaresi WJ et al. Use and costs of medical care for children and adolescents with and without attention-deficit/hyperactivity disorder. JAMA 2001; 285: 60-66
• 6 Merrill RM, Lyon JL, Baker RK et al. Attention deficit hyperactivity disorder and increased risk of injury. Adv Med Sci 2009; 54: 20-26
• 7 Pastor PN, Reuben CA. Identified attention-deficit/hyperactivity disorder and medically attended, nonfatal injuries: US school-age children, 1997–2002. Ambul Pediatr 2006; 6: 38-44
• 8 Woodward LJ, Fergusson DM, Horwood LJ. Driving outcomes of young people with attentional difficulties in adolescence. J Am Acad Child Adolesc Psychiatry 2000; 39: 627-634
• 9 Xiang H, Stallones L, Chen G et al. Nonfatal injuries among US children with disabling conditions. Am J Public Health 2005; 95: 1970-1975
• 10 Hodgkins P, Montejano L, Sasané R et al. Cost of illness and comorbidities in adults diagnosed with attention-deficit/hyperactivity disorder: a retrospective analysis. Prim Care Companion CNS Disord 2011; 13
• 11 Biederman J. Impact of comorbidity in adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2004; 65 (Suppl. 03) 3-7
• 12 Secnik K, Swensen A, Lage MJ. Comorbidities and costs of adult patients diagnosed with attention-deficit hyperactivity disorder. Pharmacoeconomics 2005; 23: 93-102
• 13 Larson K, Russ SA, Kahn RS et al. Patterns of comorbidity, functioning, and service use for US children with ADHD, 2007. Pediatrics 2011; 127: 462-470
• 14 Hinckley GB. The scourge of illicit drugs. Ensign 1989; 48
• 15 The Church of Jesus Christ of Latter-day Saints . Published by The Church of Jesus Christ of Latter-day Saints, Salt Lake City, Utah, U.S.A. Section 1982; 89: 175-176
• 16 ICD-9-CM: International Classification of Diseases, 9^th Revision; Clinical Modification. 7^th ed. Los Angeles, California: PMIC; 2006
• 17 Center of Disease Control and Prevention, Division of Human Developmental, National Center on Birth Defects and Developmental Disabilities . Attention-deficit/hyperactivity disorder (ADHD). 2013 Retrieved from http://www.cdc.gov/ncbddd/adhd/treatment.html
• 18 Chou IC, Lin CC, Sung FC et al. Attention-deficit-hyperactivity disorder increases risk of bone fracture: a population-based cohort study. Dev Med Child Neurol 2014; 56: 1111-1116
• 19 Nigg JT. Attention-deficit/hyperactivity disorder and adverse health outcomes. Clin Psychol Rev 2013; 33: 215-228
• 20 Center of Disease Control and Prevention . Increasing prevalence of parent-reported attention-deficit/hyperactivity disorder among children – United States, 2003 and 2007. MMWR. 2010. 59. 1439-1443
• 21 Pastor PN, Reuben CA. Diagnosed attention deficit hyperactivity disorder and learning disability: United States, 2004–2006. Vital Health Stat 2008; 237: 1-14
• 22 Willcutt EG. The prevalence of DSM-IV attention-deficit/hyperactivity disorder: a meta-analytic review. Neurotherapeutics 2012; 9: 490-499
• 23 Center for Behavioral Health Statistics and Quality . 2012 [Tables 7.23A and 7.23B: in results from the 2011 national survey on drug use and health: detailed tables] National Survey on Drug Use and Health. Substance Abuse and Mental Health Services Administration. Retrieved from http://www.samhsa.gov/ data/NSDUH/2011SummNatFindDetTables/Index.aspx
• 24 Marshall P, Schroeder R, O’Brien J et al. Effectiveness of symptom validity measures in identifying cognitive and behavioral symptom exaggeration in adult attention deficit hyperactivity disorder. Clin Neuropsychol 2010; 24: 1204-1237
• 25 McCabe SE, Knight JR, Teter CJ et al. Non-medical use of prescription stimulants among US college students: prevalence and correlates from a national survey. Addiction 2005; 100: 96-106
• 26 Kaskey GB. Possible interaction between an MAOI and “ecstasy”. Am J Psychiatry 1992; 149: 411-412
• 27 Markowitz JS, Patrick KS. Pharmacokinetic and pharmacodynamic drug interactions in the treatment of attention-deficit hyperactivity disorder. Clin Pharmacokinet 2001; 40: 753-772
• 28 Markowitz JS, Morrison SD, DeVane CL. Drug interactions with psychostimulants. Int Clin Psychopharmacol 1999; 14: 1-18
• 29 Stotz G, Woggon B, Angst J. Psychostimulants in the therapy of treatment-resistant depression: review of the literature and findings from a retrospective study in 65 depressed patients. Dialogues Clin Neurosci 1999; 1: 165-174
• 30 Utah Department of Health . Prescription opioid deaths in Utah. Violence and Injury Prevention Program 2012. 2011 Retrieved from http://useonlyasdirected.org/docs/RxOpioidDeaths.pdf
• 31 Van Waes V, Beverley J, Marinelli M et al Selective serotonin reuptake inhibitor antidepressant potentiate methylphenidate (Ritalin)-induced gene regulation in the adolescent striatum. Eur J Neurosci 2010; 32: 435-447
• 32 James SD. (2010, Nov8) Adderall abuse alters brain, claims a young life. ABC News Online. Retrieved from http://abcnews.go.com/Health/MindMoodNews/adderall-psychosis-suicide-college-students-abuse-study-drug/story?id=12066619
• 33 Lakhan SE, Kirchgessner A. Prescription stimulants in individuals with and without attention deficit hyperactivity disorder: misuse, cognitive impact, and adverse effects. Brain Behav 2012; 2: 661-677
• 34 Surles LK, May HJ, Garry JP. Adderall-induced psychosis in an adolescent. J Am Board Fam Pract 2002; 15: 498-500
• 35 van den Ban E, Souverein P, Meijer W et al. Association between ADHD drug use and injuries among children and adolescents. Eur Child Adolesc Psychiatry 2014; 23: 95-102